In Vitro Diagnostics (IVD) Asia-Pacific Market - Opportunities and Forecasts, 2014 - 2020

Chapter 1 INTRODUCTION

1.1 Report Description

1.2 Reason for doing the study

1.3 Key Take Away

1.4 Key Market Segments

1.5 Research Methodology

1.5.1 Secondary Research

1.5.2 Primary Research

1.5.3 Analyst tools and models

Chapter 2 EXECUTIVE SUMMARY

Chapter 3 MARKET OVERVIEW

3.1 Market definition and scope

3.2 Key Intelligence

3.2.1 Impact analysis

3.2.2 Market attractiveness analysis

3.2.3 Key Market Strategies

3.3 Governance Act and Remuneration

3.3.1 Regulations in China

3.3.2 Regulations in India

3.3.3 Regulations in Japan and Australia

3.4 Strategic Management Insights

3.4.1 Value Chain Analysis

3.4.1.1 Primary Activity

3.4.1.2 Supportive Activity

3.4.2 Porter Five Forces Analysis

3.4.2.1 Brand loyalty leads to moderate bargaining power of supplier

3.4.2.2 Varying product differentiation would lead to moderate bargaining power of buyers

3.4.2.3 Low threat from new entrants due to high entry barriers

3.4.2.4 Less intersegment substitution leads to lower threat Of substitute

3.4.2.5 Moderate competitive rivalry

3.5 Research & Analysis

3.5.1 Clinical Trials of research studies conducted for IVD market

3.6 Market Share Analysis of Asia-Pacific IVD Market (2014)

3.7 Significant Progressions in IVD technologies

3.7.1 Total Laboratory Automation (TLA)

3.7.2 Evolving markets in digital pathology

3.7.3 Omics and Genetics tests in IVD

3.7.4 Point-of-Care testing

3.7.5 Emerging technologies diagnostics and influence on IVD

3.8 Market Dynamics

3.8.1 Drivers

3.8.1.1 Increasing incidences of diseases

3.8.1.2 Technological advancements

3.8.1.3 Focus on prevention and diagnosis

3.8.1.4 Increasing healthcare expenditure

3.8.1.5 Upsurge of companion diagnostics

3.8.2 Restraints

3.8.2.1 Reimbursement issues

3.8.2.2 Stringent regulatory policies

3.8.2.3 UnAffordability of latest sophisticated tests

3.8.3 Opportunities

3.8.3.1 Potential outsourcing Opportunities in laboratory testing

3.8.3.2 Increasing popularity of personalized medicine

Chapter 4 BY TECHNIQUES

4.1 Key growth factors and opportunities

4.2 Market size and forecast

4.3 Immunoassay/Immunochemistry

4.3.1 Key growth factors and opportunities

4.3.2 Market size and forecast

4.4 Clinical Chemistry

4.4.1 Key growth factors and opportunities

4.4.2 Market size and forecast

4.4.2.1 Urine chemistry analyzers

4.4.2.2 Blood gas electrolyte analyzers

4.5 Hematology

4.5.1 Key growth factors and opportunities

4.5.2 Market size and forecast

4.5.2.1 High throughput analyzers

4.5.2.2 Medium throughput analyzers

4.5.2.3 Low throughput analyzers

4.6 Coagulation

4.6.1 Key growth factors and opportunities

4.6.2 Market size and forecast

4.7 Point of care

4.7.1 Key growth factors and opportunities

4.7.2 Market size and forecast

4.8 Microbiology

4.8.1 Key growth factors and opportunities

4.8.2 Market size and forecast

4.8.2.1 Blood culture

4.8.2.2 Pathological culture

4.8.2.3 Identification & antibiotic susceptibility testing

4.8.2.4 Others

4.9 Molecular Diagnostics

4.9.1 Key growth factors and opportunities

4.9.2 Market size and forecast

4.9.3 Infectious diseases

4.9.4 Oncology

4.9.5 Genetic diseases

4.9.6 Blood Screening

4.9.7 Others

4.10 Whole Blood Glucose

4.10.1 Key growth factors and opportunities

4.10.2 Market size and forecast

4.11 Other Clinical Techniques

4.11.1 Key growth factors and opportunities

4.11.2 Market size and forecast

4.11.3 Clinical centrifuges

4.11.4 Tissue diagnosis

4.11.5 Sample processors

4.11.6 Flow cytometry

4.11.7 Cytology

Chapter 5 BY PRODUCT TYPE

5.1 Market size and forecast

5.2 Instruments

5.2.1 Key growth factors and opportunities

5.2.2 Market size and forecast

5.3 Reagents

5.3.1 Key growth factors and opportunities

5.3.2 Market size and forecast

5.4 Data management system hardware/software

5.4.1 Key growth factors and opportunities

5.4.2 Market size and forecast

5.5 Services

5.5.1 Key growth factors and opportunities

5.5.2 Market size and forecast

Chapter 6 BY USABILITY

6.1 Market size and forecast

6.2 Disposable IVD devices

6.2.1 Key growth factors and opportunities

6.2.2Market size and forecast

6.3 Re-usable IVD devices

6.3.1 Key growth factors and opportunities

6.3.1 Market size and forecast

Chapter 7 BY APPLICATION

7.1 Market size and forecast

7.2 Infectious diseases

7.2.1 Market size and forecast

7.3 Diabetes

7.3.1 Market size and forecast

7.4 Cancer/Oncology

7.4.1 Market size and forecast

7.5 Cardiology

7.5.1 Market size and forecast

7.6 Autoimmune diseases

7.6.1 Market size and forecast

7.7 Nephrology

7.7.1 Market size and forecast

7.8 Drug Testing

7.8.1 Market size and forecast

7.9 HIV/AIDS

7.9.1 Market size and forecast

7.10 Other Applications

7.10.1 Market size and forecast

Chapter 8 BY END-USERS

8.1 Market size and forecast

8.2 Hospitals

8.2.1 Market size and forecast

8.3 Laboratory

8.3.1 Market size and forecast

8.4 Academics

8.4.1 Market size and forecast

8.5 Point-of-Care /self-testing

8.5.1 Market size and forecast

8.6 Others

8.6.1 Market size and forecast

Chapter 9 BY COUNTRIES

9.1 Market size and forecast

9.2 India

9.2.1 Competitive Analysis

9.2.2 Key Growth Factors and Opportunities

9.2.3 Market size and forecast

9.3 China

9.3.1 Competitive Analysis

9.3.2 Key Growth Factors and Opportunities

9.3.3Market size and forecast

9.4 Japan

9.4.1 Competitive Analysis

9.4.2 Key Growth Factors and Opportunities

9.4.3 Market size and forecast

9.5 Australia

9.5.1 Competitive Analysis

9.5.2 Key Growth Factors and Opportunities

9.5.3 Market size and forecast

9.6 South Korea

9.6.1 Competitive Analysis

9.6.2 Key Growth Factors and Opportunities

9.6.3 Market size and forecast

9.7 Others

9.7.1 Competitive Analysis

9.7.2 Key Growth Factors and Opportunities

9.7.3 Market size and forecast

Chapter 10 COMPANY PROFILES

10.1 Danaher Corporation.

10.1.1 Company overview

10.1.2 Company snapshot

10.1.3 Business performance

10.1.4 Key Strategies and development

10.1.5 SWOT analysis of Danaher

10.2 Vela Diagnostics

10.2.1 Company overview

10.2.2 Company snapshot

10.2.3 Key Strategies and development

10.2.4 SWOT analysis of Vela Diagnostics

10.3 Affymetrix Inc.

10.3.1 Company overview

10.3.2 Company snapshot

10.3.3Financial performance of Affymetrix Inc.

10.3.4Key Strategies and development

10.3.5SWOT analysis of Affymetrix

10.4 Alere Inc.

10.4.1 Company overview

10.4.2 Company snapshot

10.4.3 Financial performance of Alere Inc.

10.4.4 Business performance

10.4.5 Key Strategies and developments

10.4.6 SWOT analysis of Alere

10.5 BioMerieux

10.5.1 Company overview

10.5.2 Company snapshot

10.5.3 Financial performance of BioMerieux

10.5.4 Key Strategies and developments

10.5.5 SWOT analysis of BioMerieux

10.6 Roche Diagnostics.

10.6.1 Company overview

10.6.2 Company snapshot

10.6.3 Financial performance of Roche Diagnostics

10.6.4 Key Strategies and developments

10.6.5 SWOT analysis of Roche Diagnostics

10.7 Becton, Dickinson And Company

10.7.1 Company overview

10.7.2 Company snapshot

10.7.3 Financial Performance

10.7.4 Key Strategies and development

10.7.5 SWOT analysis of Becton Dickinson and Company

10.8 Bio-Rad Laboratories

10.8.1 Company overview

10.8.2 Company snapshot

10.8.3Financial Performance

10.8.4Key Strategies and developments

10.8.5SWOT analysis of Bio-Rad Laboratories

10.9 Abbott Laboratories Inc.

10.9.1 Company overview

10.9.2 Company snapshot

10.9.3 Financial Performance

10.9.4 Key Strategies and developments

10.9.5 SWOT analysis of Abbott Laboratories

10.10 Transasia Bio-Medicals Ltd.

10.10.1 Company overview

10.10.2 Company snapshot

10.10.3 Business Operating Segments

10.10.4 Key Strategies and Development

10.10.5 SWOT analysis of Transasia Bio-Medicals Ltd.

10.11 Arkray Inc.

10.11.1 Company overview

10.11.2 Company snapshot

10.11.3 Key Strategies and development

10.11.4 SWOT analysis of Arkray Inc.

10.12 Sysmex Corporation

10.12.1 Company overview

10.12.2 Company snapshot

10.12.3 Business performance

10.12.4 Key strategies and developments

10.12.5 SWOT analysis of Sysmex

10.13 Johnson & Johnson

10.13.1 Company overview

10.13.2 Company snapshot

10.13.3 Business Performance

10.13.4 Key Strategies and Development

10.13.5 SWOT analysis of Johnson & Johnson

10.14 Siemens Healthcare

10.14.1 Company overview

10.14.2 Company snapshot

10.14.3 Business performance

10.14.4 Key Strategies and development

10.14.5 SWOT analysis of Siemens

List of figure

FIG. 1 IMPACT ANALYSIS OF ASIA PACIFIC IVD MARKET (2014-2020)

FIG. 2 POTENTIAL INVESTMENT POCKETS OF APAC IVD MARKET, BY TECHNOLOGY, 2014-2020

FIG. 3 KEY MARKET STRATEGIES IN IVD MARKET

FIG. 4 TOP WINNING STRATEGIES (2011-2015)

FIG. 5 VALUE CHAIN ANALYSIS FOR IVD MARKET

FIG. 6 PORTER`S FIVE FORCES MODEL OF ASIA PACIFIC IVD MARKET

FIG. 7 MARKET SHARE ANALYSIS OF ASIA-PACIFIC IVD MARKET (2014)

FIG. 8 ASIA PACIFIC KEY FACTS ON HIV IN 2013

FIG. 9 KEY FINANCIALS OF DANAHER SALES BY SEGMENT 2013

FIG. 10 KEY FINANCIALS OF DANAHER SALES BY GEOGRAPHY 2013

FIG. 11 SWOT ANALYSIS OF DANAHER

FIG. 12 SWOT ANALYSIS OF VELA DIAGNOSTICS

FIG. 13 KEY FINANCIALS OF AFFYMETRIX INC. REVENUE, 2011-2014, $MILLION

FIG. 14 KEY FINANCIALS OF AFFYMETRIX INC. REVENUE BY SEGMENTS

FIG. 15 KEY FINANCIALS OF AFFYMETRIX INC.CORPORATION REVENUE BY GEOGRAPHY

FIG. 16 SWOT ANALYSIS OF AFFYMETRIX INC.

FIG. 17 KEY FINANCIALS OF ALERE INC. REVENUE, 2011-2014, $MILLION

FIG. 18 KEY FINANCIALS OF ALERE INC.REVENUE BY SEGMENTS

FIG. 19 KEY FINANCIALS OF ALERE INC. REVENUE BY GEOGRAPHY

FIG. 20 SWOT ANALYSIS OF ALERE INC

FIG. 21 KEY FINANCIALS OF BIOMERIEUX REVENUE, 2011-2014, $MILLION

FIG. 22 KEY FINANCIALS OF BREAKDOWN OF SALES BY APPLICATION, 2013

FIG. 23 KEY FINANCIALS OF BREAKDOWN OF SALES BY GEOGRAPHY, 2013

FIG. 24 SWOT ANALYSIS OF BIOMERIEUX

FIG. 25 KEY FINANCIALS OF ROCHE DIAGNOSTICS REVENUE, 2011-2014, $MILLION

FIG. 26 KEY FINANCIALS OF ROCHE DIAGNOSTICS REVENUES BY SEGMENT, 2014

FIG. 27 KEY FINANCIALS OF ROCHE DIAGNOSTICS SALES BY GEOGRAPHY 2014

FIG. 28 SWOT ANALYSIS OF ROCHE DIAGNOSTICS

FIG. 29 KEY FINANCIALS OF BECTON, DICKINSON AND COMPANY REVENUE, 2011-2014, $MILLION

FIG. 30 KEY FINANCIALS OF BECTON DICKINSON AND COMPANY REVENUES BY SEGMENT 2014

FIG. 31 KEY FINANCIALS OF BECTON DICKINSON AND COMPANY SALES BY GEOGRAPHY 2014

FIG. 32 SWOT ANALYSIS OF BECTON,DICKINSON AND COMPANY

FIG. 33 KEY FINANCIALS OF BIO-RAD LABORATORIES REVENUE, 2011-2014, $MILLION

FIG. 34 KEY FINANCIALS OF BIO-RAD LABORATORIES REVENUES BY SEGMENT 2013

FIG. 35 KEY FINANCIALS OF BIO-RAD LABORATORIES REVENUES BY GEOGRAPHY 2013

FIG. 36 SWOT ANALYSIS OF BIO-RAD LABORATORIES

FIG. 37 KEY FINANCIALS OF ABBOTT LABORATORIES REVENUE, 2011-2014, $MILLION

FIG. 38 KEY FINANCIALS OF ABBOTT LABORATORIES INC REVENUES BY SEGMENT 2013

FIG. 39 KEY FINANCIALS OF ABBOTT LABORATORIES INC REVENUES BY GEOGRAPHY 2013

FIG. 40 SWOT ANALYSIS OF ABBOTT LABORATORIES

FIG. 41 COMPANY SNAPSHOT OF TRANSASIA BIOMEDICALS

FIG. 42 SWOT ANALYSIS OF TRANSASIA BIO-MEDICALS LTD

FIG. 43 SWOT ANALYSIS OF ARKRAY INC.

FIG. 44 KEY FINANCIALS OF SYSMEX COMPANY REVENUES BY SEGMENT 2013

FIG. 45 KEY FINANCIALS OF SYSMEX COMPANY REVENUES BY GEOGRAPHY 2013

FIG. 46 SWOT ANALYSIS OF SYSMEX

FIG. 47 KEY FINANCIALS OF JOHNSON & JOHNSON COMPANY REVENUES BY SEGMENT 2013

FIG. 48 KEY FINANCIALS OF JOHNSON & JOHNSON COMPANY REVENUES BY GEOGRAPHY 2013

FIG. 49 SWOT ANALYSIS OF JOHNSON & JOHNSON

FIG. 50 KEY FINANCIALS OF SIEMENS COMPANY REVENUES BY SEGMENT 2013

FIG. 51 KEY FINANCIALS OF SIEMENS COMPANY REVENUES BY GEOGRAPHY 2013

FIG. 52 SWOT ANALYSIS OF SIEMENS

List of tables:

TABLE 1 CLINICAL TRIALS - IN VITRO DIAGNOSTIC DEVICES

TABLE 2 GLOBAL INCIDENCES OF DISEASES (2011, 2012 & 2030)

TABLE 3 GOVERNMENT HEALTHCARE SPENDING IN ASIA PACIFIC COUNTRIES 2011

TABLE 4 COMPARISON OF ESTIMATED HEALTHCARE EXPENDITURE IN ASIA (1999, 2015, 2030) (US$ MILLION)

TABLE 5 ASIA PACIFIC IVD MARKET, BY TECHNIQUES, VALUE, 2014-2020, ($MILLION)

TABLE 6 ASIA PACIFIC IVD TECHNIQUES MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 7 ASIA PACIFIC IVD IMMUNOASSAY/IMMUNOCHEMISTRY MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 8 ASIA PACIFIC IVD CLINICAL CHEMISTRY MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 9 ASIA PACIFIC IVD HEMATOLOGY MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 10 ASIA PACIFIC IVD COAGULATION MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 11 ASIA PACIFIC IVD POINT-OF-CARE MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 12 ASIA PACIFIC IVD MICROBIOLOGY MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 13 ASIA PACIFIC IVD MOLECULAR DIAGNOSTICS MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 14 ASIA PACIFIC IVD WHOLE BLOOD GLUCOSE MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 15 ASIA PACIFIC IVD OTHER CLINICAL TECHNIQUES MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 16 ASIA PACIFIC IVD MARKET, BY PRODUCT TYPE, VALUE, 2014-2020, ($MILLION)

TABLE 17 ASIA PACIFIC IVD , BY PRODUCT TYPE MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 18 ASIA PACIFIC IVD INSTRUMENTS MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 19 ASIA PACIFIC IVD REAGENTS MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 20 ASIA PACIFIC IVD DATA MANAGEMENT SYSTEM HARDWARE/SOFTWARE MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 21 ASIA PACIFIC IVD SERVICES MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 22 ASIA PACIFIC IVD MARKET, BY USABILITY, VALUE, 2014-2020, ($MILLION)

TABLE 23 ASIA PACIFIC IVD , BY USABILITY MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 24 ASIA PACIFIC DISPOSABLE IVD DEVICES MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 25 LIST OF MANUFACTURERS WITH RE-USABLE IVD DEVICES

TABLE 26 ASIA PACIFIC RE-USABLE IVD DEVICES MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 27 ASIA PACIFIC IVD MARKET, BY APPLICATION, VALUE, 2014-2020, ($MILLION)

TABLE 28 ASIA PACIFIC IVD , BY APPLICATION MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 29 ASIA PACIFIC IVD INFECTIOUS DISEASES MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 30 ASIA PACIFIC IVD DIABETES MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 31 ASIA PACIFIC IVD CANCER/ONCOLOGY MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 32 ASIA PACIFIC IVD CARDIOLOGY MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 33 ASIA PACIFIC IVD AUTOIMMUNE DISEASES MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 34 ASIA PACIFIC IVD NEPHROLOGY MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 35 ASIA PACIFIC IVD DRUG TESTING MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 36 ASIA PACIFIC IVD HIV/AIDS MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 37 INCIDENCE AND PREVALENCE OF DEMENTIA IN ASIA PACIFIC REGION (2005,2020 & 2050)

TABLE 38 ASIA PACIFIC IVD OTHER APPLICATION MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 39 ASIA PACIFIC IVD MARKET, BY END-USERS, VALUE, 2014-2020, ($MILLION)

TABLE 40 ASIA PACIFIC IVD , BY END-USERS MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 41 ASIA PACIFIC HOSPITAL IVD END-USER MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 42 ASIA PACIFIC LABORATORY IVD END-USER MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 43 ASIA PACIFIC ACADEMICS IVD END-USER MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 44 ASIA PACIFIC POINT-OF-CARE/SELF-TESTING IVD END-USER MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 45 ASIA PACIFIC OTHER IVD END-USER MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 46 ASIA-PACIFIC IVD MARKET, BY COUNTRIES, VALUE, 2014-2020, ($MILLION)

TABLE 47 INDIA IVD MARKET, BY TECHNIQUE, VALUE, 2014-2020, ($MILLION)

TABLE 48 REGULATORY SUMMARY FOR IVD DEVICES IN CHINA

TABLE 49 CHINA IVD MARKET, BY TECHNIQUE, VALUE, 2014-2020, ($MILLION)

TABLE 50 JAPAN IVD MARKET, BY TECHNIQUE, VALUE, 2014-2020, ($MILLION)

TABLE 51 CATEGORIZATION OF IVD DEVICES

TABLE 52 AUSTRALIA IVD MARKET, BY TECHNIQUE, VALUE, 2014-2020, ($MILLION)

TABLE 53 SOUTH KOREA IVD MARKET, BY TECHNIQUE, VALUE, 2014-2020, ($MILLION)

TABLE 54 OTHER APAC REGION IVD MARKET, BY TECHNIQUE, VALUE, 2014-2020, ($MILLION)

TABLE 55 DANAHER COMPANY SNAPSHOT

TABLE 56 VELA DIAGNOSTICS COMPANY SNAPSHOT

TABLE 57 COMPANY SNAPSHOT AFFYMETRIX INC.

TABLE 58 COMPANY SNAPSHOT ALERE INC

TABLE 59 BIOMERIEUX COMPANY SNAPSHOT

TABLE 60 COMPANY SNAPSHOT OF ROCHE DIAGNOSTICS

TABLE 61 COMPANY SNAPSHOT OF BECTON, DICKINSON AND COMPANY

TABLE 62 SNAPSHOT OF BIO-RAD LABORATORIES

TABLE 63 SNAPSHOT OF ABBOTT LABORATORIES INC

TABLE 64 TRANSASIA BIOMEDICALS OPERATING BUSINESS SEGMENTS

TABLE 65 COMPANY SNAPSHOT OF ARKRAY INC

TABLE 66 COMPANY SNAPSHOT OF SYSMEX CORPORATION

TABLE 67 JOHNSON & JOHNSON COMPANY SNAPSHOT

TABLE 68 SIEMENS COMPANY SNAPSHOT